Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2025.317 | Effectiveness of a Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients with Lung Cancer and Its Association with Brain Activity Changes | Dr. LOONG Herbert Ho Fung |
| 2025.318 | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY™ Study) | Prof. HUI David Shu Cheong |
| 2025.319 | App-assisted implementation of evidence-based management of acute intracerebral haemorrhage |
Dr. IP Bonaventure Yiu Ming 葉耀明 |
| 2025.320 | Radiation-free Assessment of Skeletal Maturity and Bone Health Status in Paediatric Spinal Deformity | Dr. LAU Adam Yiu Chung |
| 2025.321 | Organoids derived from EUS-guided tissue sampling for precision oncology in advanced pancreatic ductal adenocarcinoma | Dr. XIA Xianfeng |
| 2025.322 | Development and validation of a new scale to assess sexual problems in people with prostate cancer and to design an electronic patient-reported outcome measure for this population (ePROM-SexPCare) | Prof. NG Chi Fai |
| 2025.323 | Pilot Study on Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer | Prof. TEOH Jeremy Yuen Chun |
| 2025.324 | Establishment of Hong Kong Diabesity Register and a 3-year Randomized Clinical Trial for the Investigation of the Effectiveness of a Multicomponent Integrated Care Program in Chinese with Diabesity | Prof. KONG Alice Pik Shan |
| 2025.325 | Enhancing First-Attempt Success in Peripheral Venous Catheterization: A Randomized Pilot Study on Infrared Vein Finder Implementation for Phlebotomy Teams in Integrated Ambulatory Care Centre, Hong Kong | Ms. TANG Vivien Wai Man |
| 2025.326 | Development of Zinc Transporter ZIP10-Based Targeted Antibody-Drug Conjugates and Mechanism of Anti-Gastric Cancer |
Dr. CHEN Bonan 陳博南 |
| 2025.327 | Effectiveness of mHealth-based survivorship programme on health-related quality of life among Vietnamese colorectal cancer survivors: A randomised controlled trial | Ms. DO Pham Nhat Vi |
| 2025.328 | Effect of A Remote Counselling Programme on Screening Uptake in First-Degree Relatives of Colorectal Cancer Patients: A Randomised Controlled Trial |
Ms. DONG Bei 董贝 |
| 2025.329 | The effects of theory-guided multimodal educational (TIME) programme on the faecal occult blood test (FOBT) uptake rates among adults at average-risk of colorectal cancer: A randomized controlled trial | Ms. KWAN Siu Kuen |
| 2025.330 | Effectiveness of Virtual Reality-enhanced Interventions on Preoperative Anxiety in Adults Undergoing Elective Surgery: A 3-arm randomised controlled trial (VIPA trial) | Mr. CHAN Sin Lun |
| 2025.331 | Effectiveness of a Game-based educational workshop on Hong Kong students’ change in self-efficacy, awareness, and attitudes to drug abuse | Prof. Chan Dorothy Ngo Sheung |
| 2025.332 | Self-management supported game-based exercise and massage to promote upper limb functions and psychological outcomes among people with spasticity after stroke: An exploratory trial | Prof. Lo Suzanne Hoi Shan |
| 2025.334 | Healing with Exercises and Brain Stimulation: A Three-Arm Randomised Controlled Trial to Facilitate Symptom Control in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) Living in Subdivided Flat Units | Dr. CHAN Crystal Ying |
| 2025.335 | Butyrate and Taurine to reduce Chronic Postsurgical Pain in Adult Cardiac Surgical Patients: a double-blinded, placebo-controlled, pilot randomized controlled trial | Dr. WONG Man Kin |
| 2025.336 | Validation of the Hong Kong Database of Emotional Face (HKDEF) | Dr. WONG Wing Ho |
| 2025.337 | Primary Obesity Surgery Endoluminal 2.0 (POSE-2) Procedure for Treatment of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease |
Dr. NG STEPHEN KA KEI 吳家琦 |
| 2025.338 | Development of a Neurofeedback System to Support Emotion Visualization | Dr. WANG Yang |
| 2025.339 | Lung Cancer Biomarker: Methylation Risk Score for Early Detection and Minimal Residual Disease Monitoring | Dr. LI Siu Ching |
| 2025.341 | Establishment of a Novel Non-Invasive Biomarker Panel in Peripheral Blood Mononuclear Cells for Predicting Immunotherapy Response in Hepatocellular Carcinoma | Prof. LONG Xiaohang |
| 2025.343 | Development for AI-Powered Retrograde Intrarenal Surgery | Prof. NG Chi Fai |
| 2025.344 | The 2023 ACR/ EULAR Classification Criteria for the thromboembolic antiphospholipid syndrome: a validation study in Hong Kong Chinese patients |
Dr. HO Ling Yin 何令妍 |
| 2025.345 | The 2023 ACR/ EULAR Classification Criteria for the thromboembolic antiphospholipid syndrome: a validation study in Hong Kong Chinese patients |
Prof. SO Ho 蘇皓 |
| 2025.346 | The 2023 ACR/ EULAR Classification Criteria for the thromboembolic antiphospholipid syndrome: a validation study in Hong Kong Chinese patients |
Dr. TANG Hoi San 鄧凱珊 |
| 2025.347 | Impact of intrinsic capacity on the patient-reported and clinical outcomes of geriatric patients | Dr. LEE Jenny Shun Wah |
| 2025.348 | Understanding Mental Health Screening for Caregivers of Children with Developmental Concerns: Perspectives and Barriers Among Caregivers and Healthcare Providers Across Global Contexts | Dr. WONG Wing Ho |
| 2025.349 | Spatial multi-omics analysis of tumor-infiltrating regulatory B cells in ovarian cancer with lymphotoxin overexpression in ovarian cancer typing diagnosis and recurrence prediction |
Prof. WANG Ronald 黃志超 |
| 2025.350 | The Development of an Intelligent System for Real-time Automated Anatomical Recognition System During Endoscopic Ultrasound | Prof. CHAN Shannon |
| 2025.351 | Long-term effects and healthcare costs of extreme heat on cardiovascular complications in Chinese patients with type 2 diabetes | Dr. LAU Siu Him |
| 2025.352 | Review of hip fracture patients with history of fragility fracture | Dr. FUNG Kwun Ping |
| 2025.353 | An in-vitro study to examine the activity of Avibactam-aztreonam against Carbapenem resistant gram-negative bacilli in a tertiary referral laboratory in Hong Kong | Dr. LAI Christopher Koon Chi |
| 2025.354 | Evaluation of responses generated by ChatGPT and DeepSeek to drug information questions in hospital setting of Hong Kong | Prof. YOU Joyce Hoi Sze |
| 2025.355 | Retrospective Study Protocol – Data collection for AutoTV and AutoView |
Prof. LEE Alex Pui Wai 李沛威 |
| 2025.356 | Development for AI-Powered Nasal Cavity Reconstruction | Prof. TONG Michael C.F. |
| 2025.357 | Reconstruction and application of interactive virtual environments with real-time navigation for training, planning and rehearsal of transcanal endoscopic ear surgery | Dr. CHANG Wai Tsz |
| 2025.358 | Investigating the Predictive Power of Coronary Plaque for Major Adverse Cardiovascular Events (MACE) in Psoriatic Arthritis: A 10-year Retrospective Study | Prof. TAM Lai Shan |
| 2025.359 | A two-part phase 1 open-label safety and pharmacokinetic study of intravenous RC220 in combination with doxorubicin in adult patients with solid tumours | Dr. LOONG Herbert Ho Fung |
| 2025.360 | Establishment of New Territories East Cluster Biliary Tract Cancer Database | Prof. CHAN Stephen Lam |
| 2025.361 | Medication adherence patterns and treatment beliefs of patients using proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) | Dr. TSANG Chiu Chi |
| 2025.362 | Phase I-II study of JS207 a bispecific antibody against PD1-VEGF in the treatment of recurrent/metastatic nasopharyngeal carcinoma | Prof. MA Brigette Buig Yue |
| 2025.363 | Epidemiological analytics in the realm of big data for the enhancement of the understanding of orthopaedic conditions | Prof. LUI Pauline Po Yee |
| 2025.364 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY) | Prof. HUI David Shu Cheong |
| 2025.365 | A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06) | Dr. LOONG Herbert Ho Fung |
| 2025.366 | A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Dr. LI Molly Siu Ching |
| 2025.367 | Retention rate of adalimumab bio-original and biosimilars in rheumatic diseases: a real-world study from the Hong Kong Biologics Registry |
Dr. TANG Hoi San 鄧凱珊 |
| 2025.368 | Retention rate of adalimumab bio-original and biosimilars in rheumatic diseases: a real-world study from the Hong Kong Biologics Registry |
Dr. TAM Lydia Ho Pui 譚皓珮 |
| 2025.369 | Retention rate of adalimumab bio-original and biosimilars in rheumatic diseases: a real-world study from the Hong Kong Biologics Registry |
Dr. HO Ling Yin 何令妍 |
Page 267 of 288.